Options
Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
Journal
The Journal of antimicrobial chemotherapy
Journal Volume
79
Journal Issue
5
Start Page
1196
End Page
1200
ISSN
1460-2091
Date Issued
2024-05-02
Author(s)
Type
journal article